Lifecore Biomedical (FRA:LDE) Accounts Payable: €6.26 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:LDE Lifecore Biomedical Inc FRA:LDE
59 GF Score
Price €3.80
GF Value €4.81
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Lifecore Biomedical Accounts Payable?

Lifecore Biomedical FRA:LDE +6.15% 59 Accounts Payable is €6.26 Mil as of Jun. 2026. GuruFocus rates FRA:LDE with a GF Score™ of 59/100 and a GF Value™ of €4.81 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Lifecore Biomedical's Accounts Payable for the quarter that ended in Jun. 2026 was €6.26 Mil.

Lifecore Biomedical's quarterly Accounts Payable declined from May. 2025 (€7.24 Mil) to Mar. 2026 (€5.76 Mil) but then increased from Mar. 2026 (€5.76 Mil) to Jun. 2026 (€6.26 Mil).

Lifecore Biomedical's annual Accounts Payable declined from May. 2023 (€20.73 Mil) to May. 2024 (€15.05 Mil) and declined from May. 2024 (€15.05 Mil) to May. 2025 (€7.24 Mil).

Lifecore Biomedical Accounts Payable Related Terms

Lifecore Biomedical Accounts Payable Historical Data

* Premium members only.

The historical data trend for Lifecore Biomedical's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lifecore Biomedical Accounts Payable Chart

Lifecore Biomedical Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23 May24 May25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.33 12.09 20.73 15.05 7.24

Lifecore Biomedical Quarterly Data
Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Mar26 Jun26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.17 7.12 7.24 5.76 6.26
FRA:LDE
59GF Score
Lifecore Biomedical Inc FRA:LDE
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lifecore Biomedical Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of €6.26 Mil mean?
Lifecore Biomedical (FRA:LDE) has a Accounts Payable of €6.26 Mil as of Jun. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Lifecore Biomedical and its competitors.
Is Lifecore Biomedical's Accounts Payable too high?
Lifecore Biomedical's current Accounts Payable is €6.26 Mil. Overall, Lifecore Biomedical has a GF Score™ of 59/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lifecore Biomedical's Accounts Payable compare to ADCT and DERM?
Lifecore Biomedical's Accounts Payable of €6.26 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Drug Manufacturers company?
A good Accounts Payable depends on the Drug Manufacturers industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Lifecore Biomedical and its competitors. Lifecore Biomedical's current Accounts Payable is €6.26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lifecore Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Lifecore Biomedical (FRA:LDE) is currently considered Modestly Undervalued. The stock's GF Value™ is €4.81, compared to a current price of €3.80 — trading 21% below its estimated fair value. The current Accounts Payable is €6.26 Mil. Lifecore Biomedical's overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Lifecore Biomedical (FRA:LDE), the current Accounts Payable is €6.26 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lifecore Biomedical (FRA:LDE) Overvalued in 2026?

Based on GuruFocus' analysis, Lifecore Biomedical stock appears to be undervalued. The current stock price of €3.80 is trading 21% below its estimated GF Value™ of €4.81. GuruFocus considers Lifecore Biomedical to be Modestly Undervalued.

Key valuation signals for FRA:LDE:

  • Accounts Payable: €6.26 Mil
  • GF Value™: €4.81 vs. price of €3.80 (21% below fair value)
  • GF Score™: 59/100 with 3 warning signs

No single metric tells the full story. See the FRA:LDE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lifecore Biomedical Business Description

Other Exchanges LFCR:USA
Address 3515 Lyman Boulevard, Chaska, MN, USA, 55318
Lifecore Biomedical Inc. is a fully integrated contract development and manufacturing organization (CDMO) based in the United States. The company specializes in the development, fill, and finish of complex sterile injectable pharmaceutical products, including syringes, vials, and cartridges, serving pharmaceutical and biotechnology customers. Its CDMO segment provides services spanning formulation, process development, and aseptic manufacturing for injectable drug products. In addition, Lifecore manufactures and sells hyaluronic acid (HA) for use in medical devices and pharmaceutical applications, including ophthalmic and orthopedic products. The company generates revenue through CDMO service contracts and HA product sales, with customers primarily in the United States and other international markets. Lifecore operates manufacturing facilities in the United States and focuses on sterile injectable capacity and HA fermentation.
59GF Score

Get the complete analysis for FRA:LDE

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.80
Price
€4.81
GF Value